Statistics
Total Visits
| Views | |
|---|---|
| Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance | 340 |
Total Visits Per Month
| June 2024 | July 2024 | August 2024 | September 2024 | October 2024 | November 2024 | December 2024 | January 2025 | February 2025 | March 2025 | April 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance | 7 | 11 | 20 | 21 | 9 | 4 | 7 | 14 | 6 | 15 | 7 |
File Visits
| Views | |
|---|---|
| Cid_Clinical.pdf | 333 |
Top country views
| Views | |
|---|---|
| United States | 194 |
| Spain | 22 |
| Germany | 21 |
| Belgium | 14 |
| China | 10 |
| Ukraine | 9 |
| Brazil | 7 |
| Sweden | 7 |
| Ireland | 6 |
| Australia | 4 |
Top cities views
| Views | |
|---|---|
| Ashburn | 45 |
| Fairfield | 30 |
| Menlo Park | 17 |
| San Mateo | 17 |
| A Coruña | 15 |
| Louisville | 13 |
| Cambridge | 9 |
| San Diego | 9 |
| Dublin | 5 |
| Jacksonville | 5 |
